SlideShare a Scribd company logo
1 of 26
Download to read offline
ADVERSE EVENT/
SERIOUS ADVERSE
EVENT REPORTING
IN CLINICAL TRIALS
Ashish Singh parihar
OVERVIEW
 Important Terms and Their Definitions
 ICH-GCP Guidelines for AE/SAE
Reporting
 Case
Terms And Their Definitions
 Adverse Event
 Any untoward or unfavorable medical occurrence in a
human subject, including any abnormal sign,
symptom, or disease, temporally associated with the
subject’s participation in the research, whether or not
considered related to the subject’s participation in the
research.
 An AE may be expected or unexpected, related or
unrelated to the subject’s participation in the research,
local or non-local, and serious or not serious.
 The study investigator is responsible for determining
the status of an event.
Conti…
 Adverse Reaction (AR)
 Any untoward and unintended responses to an
investigational medicinal product related to any
dose administered
 Unexpected Adverse Reaction (UAR)
 An adverse reaction, the nature or severity of
which is not consistent with the applicable
product information (e.g. investigator’s brochure
for an unauthorized investigational product or
summary of product characteristics for an
authorized product)
Conti…..
 Serious Adverse Event (SAE) or Serious
Adverse Reaction (SAR) or Suspected
Unexpected Serious Adverse Reaction
(SUSAR)
Any AE, AR or UAR that at any dose:
◦ results in death
◦ is life-threatening*
◦ requires hospitalization or prolongation of
existing hospitalization
◦ results in persistent or significant disability or
incapacity
◦ consists of a congenital anomaly or birth
defect
Common Terminology Criteria for
Adverse Events v3.0 (CTCAE
 SAE/AE will be assessed as per the
following grades
 Grade 1: Mild AE
 Grade 2: Moderate AE
 Grade 3: Severe AE
 Grade 4: Life-threatening or disabling
AE
 Grade 5: Death related to AE
ICH-GCP Guidelines for Safety
Reporting
 All serious adverse events (SAEs) should be reported
immediately to the sponsor except for those SAEs that the
protocol or other document (e.g., Investigator's Brochure)
identifies as not needing immediate reporting.
 The immediate reports should be followed promptly by
detailed, written reports.
 The immediate and follow-up reports should identify
subjects by unique code numbers assigned to the trial
subjects rather than by the subjects' names, personal
identification numbers, and/or addresses.
 The investigator should also comply with the applicable
regulatory requirement(s) related to the reporting of
unexpected serious adverse drug reactions to the regulatory
authority(ies) and the IRB/IEC.
Conti….
 4.11.2 Adverse events and/or laboratory
abnormalities identified in the protocol as
critical to safety evaluations should be reported
to the sponsor according to the reporting
requirements and within the time periods
specified by the sponsor in the protocol.
 4.11.3 For reported deaths, the investigator
should supply the sponsor and the IRB/IEC with
any additional requested information (e.g.,
autopsy reports and terminal medical reports)
Notification guidelines
 Regulation 32 sets out the following responsibilities for
the notification of adverse events to sponsors:
1. An investigator shall report any SAE that occurs in a
subject at a trial site immediately* to the sponsor
(unless covered by point 2 below). This immediate
report may be made either orally or in writing as long
as detailed written report follows the immediate
report.
2. The sponsor may specify in the protocol certain
SAEs that an investigator does not have to report
immediately. The protocol should state how and when
these events should be reported.
Appendix XI Template
 Data Elements of AE/SAE should be filled in Appendix
XI form and submitted
case
study
on Accelerated Hypertension
Case Details
The Subject was Screened on 25/mar/2014 and he
underwent placebo Run-in and Lipid stabilization
on 25/mar/2014 & he is still in screening period.
The subject experienced left sided chest pain
which was non-radiating and not associated with
sweating on 9/Apr/2014 at 8.30 and he went to a
local hospital where ECG and other physical
examination were done. Upon examination the
subjects BP was found to be 150/100mm/Hg and his
ECG showed possibilities of IMWI( Inferior Wall
Myocardial Infraction).
Conti….
 He was given the following medications
 Tablet Asprin 300mg Stat
 Tablet Clopidogrel 600mg Stat
 Tablet Atorvastatin 80mg Stat
 Tablet Isosorbide Dinitrate 5mg Stat
 Tablet Metoprolol 25mg Stat
The subject called to the site at 13:00 and
he was asked to come to the hospital
immediately
Conti…
..as per PI’s discretion. He came to the site at
17:25. he was examined by the PI who advised
the patient to get admitted to medicine
department for further treatment and
consultation under the PI’s observation. After
considering the lab results and symptoms ,
subject was diagnosed of Accelerated
Hypertension
Conti…
After 4 days of hospitalization the subject got
discharged since he has shown improvement.
 Discharge Medications
• Tablet Isosorbide Mononitrate 30mg OD
• Tablet Metmorfin 500mg OD
• Tablet Ramipril 2.5mg OD
• Tablet Metoprolol 25mg OD
• Tablet Aspirin 75mg OD
Risk Assessment
Assessment was done by PI to check
whether it was SAE/AE.
• The subject got hospitalized as per
PI’s discretion therefore this is
termed/considered as an Adverse
Event (As per Drug and Cosmetic act
definition).
• On assessment PI found that the SAE
was not related to Study drug so any
action was not taken on the study
drug.
Conti…
 According to the standard grading system the
SAE was graded as
 GRADE 3 – Severe (Require Hospitalization)
 Appendix XI form
 As per the guidelines the Appendix XI form was
filled for reporting of SAE
SAE Reporting – Appendix XI
 Appendix XI details
Details in Appendix XI were filled as follows
1. Patient Details
• Initials and other relevent identifier – KMS, IP
524002
• Gender – Male
• Age and DOB – 52 years, DOB-08/JAN/1962
• Weight - 58kgs
• Height – 170cm
Conti…
2. Suspected Drug : SAE not related to the IP
• Generic name of the drug – blinded ADT 124
• Indication for which suspect drug was
prescribed – dyslipidemia
• Dosage form and strength – Auto-Injector 140
mg/ml
• Daily dose and regimen – Blinded information
• Route of Administration – IV
• Starting Date and Time of day – NA (Subject
was still undergoing screening)
Other Treatments..
3. Other Treatments – provide same information for
concomitant drugs
Generic
name
Indication
s for drug
was
prescribd
Dosage
Form and
strength
Daily
dose and
regimen
Route of
administr
ation
Starting
date and
time of
day
Stopping
Date and
time
Isosorbide
Mononitrat
e
Chest
Pain
30mg OD Oral 9/APR/14 Cont.
Metformin Diabetes
Mellitus
500mg OD Oral 9/APR/14 Cont.
Asprin Myocardia
l
Infraction
75mg OD Oral 9/APR/14 Cont.
Ramipril Hypertensi
on
1.25mg OD Oral 9/APR/14 Cont.
Metaprolol Hypertensi
on
25mg OD Oral 9/APR/14 Cont.
Appendix XI
 4. Details of Suspected Adverse event were
written in detailed manner (as per patient details
in previous slides), full description of reaction
including body site and severity, as well as the
criterion for regarding the report as serious . In
addition to a description of the reported signs
and symptoms, diagnoses for the reaction were
written in a detailed form. Medications
prescribed and details of hospitalization were
mentioned.
Conti…
 Start date of onset of reaction – 9/Apr/14
 Stop date or duration of reaction – 12/Apr/14
 Setting – Hospital
5. Outcome – Resolved
6. Details of the Investigator, name, Phn no,
profession, address were mentioned.
Date of reporting – 18/Apr/14
Date of reporting to EC – 18/Apr/14 and
investigator signed the form
Safety Reporting
 After the phone call from the subject PI assessed
the event as SAE and reported it to the members
of sponsors/CRO by mail.
 PI prepared a Submission letter for SAE , filled
the details of appendix XI form, CIOMS form,
filled and updated the event in e-CRF and in
CRF
 Submission letter and covering letter was
submitted to EC and DCGI for reporting the
SAE on 10th April 2014 i.e. next day of the
event( as per guidelines and regulatory
requirements)
Conti…
 EC and DCGI reviewed the SAE report and
acknowledged it and sent a Receipt .
 After the discharge of subject from the hospital
PI prepared a follow up report and submitted it
to EC and DCGI.
 Outcome - SAE was resolved as the subject
recovered from Accelerated Hypertension
Conti…
 All the forms, acknowledgments, lab
reports, Letters and other documents
were filed in patient file for further
monitoring and audits.
 Subject was randomized and he
continued his participation in the study
AE/SAE reporting in clinical trials

More Related Content

What's hot

Updated Timelines for Reporting of SAE
Updated Timelines for Reporting of SAEUpdated Timelines for Reporting of SAE
Updated Timelines for Reporting of SAENaveen Kumar Upadhyay
 
Site & investigator selection
Site & investigator selectionSite & investigator selection
Site & investigator selectionMukesh Jaiswal
 
Sponsor Responsibilities ppt
Sponsor  Responsibilities pptSponsor  Responsibilities ppt
Sponsor Responsibilities pptSantosh Zarkariya
 
Essential documents
Essential documentsEssential documents
Essential documentsRajeev Sahai
 
Designing of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameedDesigning of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameedRumana Hameed
 
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Dr B Naga Raju
 
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...TMF Fundamentals - An Introduction to Better Trial Master File Management - M...
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...Montrium
 
Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]siddharthchachad
 
Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.  Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe. KapilKumar198
 
Electronic Data Capture & Remote Data Capture
Electronic Data Capture & Remote  Data CaptureElectronic Data Capture & Remote  Data Capture
Electronic Data Capture & Remote Data CaptureCRB Tech
 
management of clinical trials: sponser perspective from falgun vyas
management of clinical trials: sponser perspective from falgun vyasmanagement of clinical trials: sponser perspective from falgun vyas
management of clinical trials: sponser perspective from falgun vyasFalgun Vyas
 
Clinical study and gcp
Clinical study and gcpClinical study and gcp
Clinical study and gcpGaurav Kr
 

What's hot (20)

Updated Timelines for Reporting of SAE
Updated Timelines for Reporting of SAEUpdated Timelines for Reporting of SAE
Updated Timelines for Reporting of SAE
 
Site & investigator selection
Site & investigator selectionSite & investigator selection
Site & investigator selection
 
ICH and GCP by Naveen
ICH and GCP by NaveenICH and GCP by Naveen
ICH and GCP by Naveen
 
Cra responsebility
Cra responsebilityCra responsebility
Cra responsebility
 
Sponsor Responsibilities ppt
Sponsor  Responsibilities pptSponsor  Responsibilities ppt
Sponsor Responsibilities ppt
 
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand PirouziICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
ICH - E2D Pharmacovigilance and Drug Safety - Professor Peivand Pirouzi
 
eTMF ppt
eTMF ppteTMF ppt
eTMF ppt
 
Essential documents
Essential documentsEssential documents
Essential documents
 
Designing of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameedDesigning of clinical study protocol rumana hameed
Designing of clinical study protocol rumana hameed
 
Ich gcp
Ich gcpIch gcp
Ich gcp
 
Audits & Inspections in Clinical Research
Audits & Inspections in Clinical ResearchAudits & Inspections in Clinical Research
Audits & Inspections in Clinical Research
 
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
 
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...TMF Fundamentals - An Introduction to Better Trial Master File Management - M...
TMF Fundamentals - An Introduction to Better Trial Master File Management - M...
 
Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]Volume 9 A Guidelines On Pharmacovigilance[1]
Volume 9 A Guidelines On Pharmacovigilance[1]
 
ADVERSE EVENT REPORTING
ADVERSE EVENT REPORTINGADVERSE EVENT REPORTING
ADVERSE EVENT REPORTING
 
Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.  Regulation Governing Clinical Trials In India,USA and Europe.
Regulation Governing Clinical Trials In India,USA and Europe.
 
Schedule Y-2019
Schedule Y-2019Schedule Y-2019
Schedule Y-2019
 
Electronic Data Capture & Remote Data Capture
Electronic Data Capture & Remote  Data CaptureElectronic Data Capture & Remote  Data Capture
Electronic Data Capture & Remote Data Capture
 
management of clinical trials: sponser perspective from falgun vyas
management of clinical trials: sponser perspective from falgun vyasmanagement of clinical trials: sponser perspective from falgun vyas
management of clinical trials: sponser perspective from falgun vyas
 
Clinical study and gcp
Clinical study and gcpClinical study and gcp
Clinical study and gcp
 

Similar to AE/SAE reporting in clinical trials

Nouvelles exigences en pharmacovigilance - Aprova - Rencontres de la Recherch...
Nouvelles exigences en pharmacovigilance - Aprova - Rencontres de la Recherch...Nouvelles exigences en pharmacovigilance - Aprova - Rencontres de la Recherch...
Nouvelles exigences en pharmacovigilance - Aprova - Rencontres de la Recherch...PharmaSuccess
 
Chl hp-ipsg .01 patient identification-4
Chl hp-ipsg .01 patient identification-4Chl hp-ipsg .01 patient identification-4
Chl hp-ipsg .01 patient identification-4cicaklomen
 
ICH E2A GUIDELINE
ICH E2A GUIDELINEICH E2A GUIDELINE
ICH E2A GUIDELINEsathishat9
 
Guidelines on the collection verification and submission of reports on advers...
Guidelines on the collection verification and submission of reports on advers...Guidelines on the collection verification and submission of reports on advers...
Guidelines on the collection verification and submission of reports on advers...Serkan Kaçar
 
Sop pre-employment medical examination
Sop pre-employment medical examinationSop pre-employment medical examination
Sop pre-employment medical examinationladdha1962
 
Spontenous adr reporting
Spontenous adr reportingSpontenous adr reporting
Spontenous adr reportingSONALPANDE5
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSKatalyst HLS
 
Medical Examination Form
Medical Examination FormMedical Examination Form
Medical Examination FormLeona Chin
 
DRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptxDRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptxAmeena Kadar
 
triage ppt.pptx
triage ppt.pptxtriage ppt.pptx
triage ppt.pptxVermaG3
 
MR documentation Presentation
MR documentation PresentationMR documentation Presentation
MR documentation PresentationAlaa Elbaraa
 
Periodic medical examination
Periodic medical examinationPeriodic medical examination
Periodic medical examinationladdha1962
 
MAM MOTORSPORTS MALAYSIA Medical Examination Form.pdf
MAM MOTORSPORTS MALAYSIA Medical Examination Form.pdfMAM MOTORSPORTS MALAYSIA Medical Examination Form.pdf
MAM MOTORSPORTS MALAYSIA Medical Examination Form.pdfLeona Chin
 

Similar to AE/SAE reporting in clinical trials (20)

Medical Record Management
Medical Record Management   Medical Record Management
Medical Record Management
 
Nouvelles exigences en pharmacovigilance - Aprova - Rencontres de la Recherch...
Nouvelles exigences en pharmacovigilance - Aprova - Rencontres de la Recherch...Nouvelles exigences en pharmacovigilance - Aprova - Rencontres de la Recherch...
Nouvelles exigences en pharmacovigilance - Aprova - Rencontres de la Recherch...
 
Chl hp-ipsg .01 patient identification-4
Chl hp-ipsg .01 patient identification-4Chl hp-ipsg .01 patient identification-4
Chl hp-ipsg .01 patient identification-4
 
AEFI guidelines
AEFI guidelinesAEFI guidelines
AEFI guidelines
 
adverse drug reactions management
adverse drug reactions  managementadverse drug reactions  management
adverse drug reactions management
 
ICH E2A GUIDELINE
ICH E2A GUIDELINEICH E2A GUIDELINE
ICH E2A GUIDELINE
 
Guidelines on the collection verification and submission of reports on advers...
Guidelines on the collection verification and submission of reports on advers...Guidelines on the collection verification and submission of reports on advers...
Guidelines on the collection verification and submission of reports on advers...
 
ICH GCP
ICH GCPICH GCP
ICH GCP
 
ich gcp
ich gcpich gcp
ich gcp
 
Sop pre-employment medical examination
Sop pre-employment medical examinationSop pre-employment medical examination
Sop pre-employment medical examination
 
Spontenous adr reporting
Spontenous adr reportingSpontenous adr reporting
Spontenous adr reporting
 
Safety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLSSafety_Data_Reconciliation_Katalyst HLS
Safety_Data_Reconciliation_Katalyst HLS
 
09 aefi shani
09 aefi shani09 aefi shani
09 aefi shani
 
Medical Examination Form
Medical Examination FormMedical Examination Form
Medical Examination Form
 
DRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptxDRUG SAFETY REPORTING.pptx
DRUG SAFETY REPORTING.pptx
 
triage ppt.pptx
triage ppt.pptxtriage ppt.pptx
triage ppt.pptx
 
MR documentation Presentation
MR documentation PresentationMR documentation Presentation
MR documentation Presentation
 
Periodic medical examination
Periodic medical examinationPeriodic medical examination
Periodic medical examination
 
MAM MOTORSPORTS MALAYSIA Medical Examination Form.pdf
MAM MOTORSPORTS MALAYSIA Medical Examination Form.pdfMAM MOTORSPORTS MALAYSIA Medical Examination Form.pdf
MAM MOTORSPORTS MALAYSIA Medical Examination Form.pdf
 
GCP training .pptx.pptx
GCP training .pptx.pptxGCP training .pptx.pptx
GCP training .pptx.pptx
 

More from Dr. Ashish singh parihar

Most common source data related issues in India
Most common source data related issues in IndiaMost common source data related issues in India
Most common source data related issues in IndiaDr. Ashish singh parihar
 
Audit, inspection and monitoring in clinical trial by Ashish singh parihar
Audit, inspection and monitoring in clinical trial by Ashish singh pariharAudit, inspection and monitoring in clinical trial by Ashish singh parihar
Audit, inspection and monitoring in clinical trial by Ashish singh pariharDr. Ashish singh parihar
 
Measurement of outcomes in pharacoepidemiology
Measurement of outcomes in pharacoepidemiologyMeasurement of outcomes in pharacoepidemiology
Measurement of outcomes in pharacoepidemiologyDr. Ashish singh parihar
 

More from Dr. Ashish singh parihar (20)

Clinical trial monitoring
Clinical trial monitoringClinical trial monitoring
Clinical trial monitoring
 
Informed consent process in India
Informed consent process in IndiaInformed consent process in India
Informed consent process in India
 
Most common source data related issues in India
Most common source data related issues in IndiaMost common source data related issues in India
Most common source data related issues in India
 
ICH-GCP E6 R2 ALCOA+C Principles
ICH-GCP E6 R2 ALCOA+C PrinciplesICH-GCP E6 R2 ALCOA+C Principles
ICH-GCP E6 R2 ALCOA+C Principles
 
Drug discovery, development and approches
Drug discovery, development and approchesDrug discovery, development and approches
Drug discovery, development and approches
 
Audit, inspection and monitoring in clinical trial by Ashish singh parihar
Audit, inspection and monitoring in clinical trial by Ashish singh pariharAudit, inspection and monitoring in clinical trial by Ashish singh parihar
Audit, inspection and monitoring in clinical trial by Ashish singh parihar
 
Pharmacoepidemiology and risk management
Pharmacoepidemiology and risk management Pharmacoepidemiology and risk management
Pharmacoepidemiology and risk management
 
Hospital Pharmaco-epidemiology
Hospital Pharmaco-epidemiology Hospital Pharmaco-epidemiology
Hospital Pharmaco-epidemiology
 
Drug induced birth defect
Drug induced birth defectDrug induced birth defect
Drug induced birth defect
 
MedDRA
MedDRAMedDRA
MedDRA
 
Pharmacovigilance program of India
Pharmacovigilance program of IndiaPharmacovigilance program of India
Pharmacovigilance program of India
 
informed consent
informed consentinformed consent
informed consent
 
Ethical review
Ethical reviewEthical review
Ethical review
 
clinical trial designs
clinical trial designsclinical trial designs
clinical trial designs
 
codes of ethics
codes of ethicscodes of ethics
codes of ethics
 
Medwatch and FAERS database
Medwatch and FAERS databaseMedwatch and FAERS database
Medwatch and FAERS database
 
Measurement of outcomes in pharacoepidemiology
Measurement of outcomes in pharacoepidemiologyMeasurement of outcomes in pharacoepidemiology
Measurement of outcomes in pharacoepidemiology
 
Byasian nural network BCPNN
Byasian nural network BCPNNByasian nural network BCPNN
Byasian nural network BCPNN
 
Bias and confounding
Bias and confoundingBias and confounding
Bias and confounding
 
Study design
Study designStudy design
Study design
 

Recently uploaded

History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingSakthi Kathiravan
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Prerana Jadhav
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..AneriPatwari
 
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxDr Bilal Natiq
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxpdamico1
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxdrashraf369
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!ibtesaam huma
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdfDolisha Warbi
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMADivya Kanojiya
 

Recently uploaded (20)

History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 
LESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursingLESSON PLAN ON fever.pdf child health nursing
LESSON PLAN ON fever.pdf child health nursing
 
Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.Presentation on General Anesthetics pdf.
Presentation on General Anesthetics pdf.
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..PHYSIOTHERAPY IN HEART TRANSPLANTATION..
PHYSIOTHERAPY IN HEART TRANSPLANTATION..
 
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptxL1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
L1.INTRODUCTION to ENDOCRINOLOGY MEDICINE.pptx
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptxPresentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
Presentation for Bella Mahl 2024-03-28-24-MW-Overview-Bella.pptx
 
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptxPERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
PERFECT BUT PAINFUL TKR -ROLE OF SYNOVECTOMY.pptx
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!Biomechanics- Shoulder Joint!!!!!!!!!!!!
Biomechanics- Shoulder Joint!!!!!!!!!!!!
 
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS  CLASSIFICATIONS.pdfLUNG TUMORS AND ITS  CLASSIFICATIONS.pdf
LUNG TUMORS AND ITS CLASSIFICATIONS.pdf
 
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMAANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
ANTI-DIABETICS DRUGS - PTEROCARPUS AND GYMNEMA
 

AE/SAE reporting in clinical trials

  • 1. ADVERSE EVENT/ SERIOUS ADVERSE EVENT REPORTING IN CLINICAL TRIALS Ashish Singh parihar
  • 2. OVERVIEW  Important Terms and Their Definitions  ICH-GCP Guidelines for AE/SAE Reporting  Case
  • 3. Terms And Their Definitions  Adverse Event  Any untoward or unfavorable medical occurrence in a human subject, including any abnormal sign, symptom, or disease, temporally associated with the subject’s participation in the research, whether or not considered related to the subject’s participation in the research.  An AE may be expected or unexpected, related or unrelated to the subject’s participation in the research, local or non-local, and serious or not serious.  The study investigator is responsible for determining the status of an event.
  • 4. Conti…  Adverse Reaction (AR)  Any untoward and unintended responses to an investigational medicinal product related to any dose administered  Unexpected Adverse Reaction (UAR)  An adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g. investigator’s brochure for an unauthorized investigational product or summary of product characteristics for an authorized product)
  • 5. Conti…..  Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR) or Suspected Unexpected Serious Adverse Reaction (SUSAR) Any AE, AR or UAR that at any dose: ◦ results in death ◦ is life-threatening* ◦ requires hospitalization or prolongation of existing hospitalization ◦ results in persistent or significant disability or incapacity ◦ consists of a congenital anomaly or birth defect
  • 6. Common Terminology Criteria for Adverse Events v3.0 (CTCAE  SAE/AE will be assessed as per the following grades  Grade 1: Mild AE  Grade 2: Moderate AE  Grade 3: Severe AE  Grade 4: Life-threatening or disabling AE  Grade 5: Death related to AE
  • 7. ICH-GCP Guidelines for Safety Reporting  All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting.  The immediate reports should be followed promptly by detailed, written reports.  The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.  The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.
  • 8. Conti….  4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.  4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports)
  • 9. Notification guidelines  Regulation 32 sets out the following responsibilities for the notification of adverse events to sponsors: 1. An investigator shall report any SAE that occurs in a subject at a trial site immediately* to the sponsor (unless covered by point 2 below). This immediate report may be made either orally or in writing as long as detailed written report follows the immediate report. 2. The sponsor may specify in the protocol certain SAEs that an investigator does not have to report immediately. The protocol should state how and when these events should be reported.
  • 10. Appendix XI Template  Data Elements of AE/SAE should be filled in Appendix XI form and submitted
  • 12. Case Details The Subject was Screened on 25/mar/2014 and he underwent placebo Run-in and Lipid stabilization on 25/mar/2014 & he is still in screening period. The subject experienced left sided chest pain which was non-radiating and not associated with sweating on 9/Apr/2014 at 8.30 and he went to a local hospital where ECG and other physical examination were done. Upon examination the subjects BP was found to be 150/100mm/Hg and his ECG showed possibilities of IMWI( Inferior Wall Myocardial Infraction).
  • 13. Conti….  He was given the following medications  Tablet Asprin 300mg Stat  Tablet Clopidogrel 600mg Stat  Tablet Atorvastatin 80mg Stat  Tablet Isosorbide Dinitrate 5mg Stat  Tablet Metoprolol 25mg Stat The subject called to the site at 13:00 and he was asked to come to the hospital immediately
  • 14. Conti… ..as per PI’s discretion. He came to the site at 17:25. he was examined by the PI who advised the patient to get admitted to medicine department for further treatment and consultation under the PI’s observation. After considering the lab results and symptoms , subject was diagnosed of Accelerated Hypertension
  • 15. Conti… After 4 days of hospitalization the subject got discharged since he has shown improvement.  Discharge Medications • Tablet Isosorbide Mononitrate 30mg OD • Tablet Metmorfin 500mg OD • Tablet Ramipril 2.5mg OD • Tablet Metoprolol 25mg OD • Tablet Aspirin 75mg OD
  • 16. Risk Assessment Assessment was done by PI to check whether it was SAE/AE. • The subject got hospitalized as per PI’s discretion therefore this is termed/considered as an Adverse Event (As per Drug and Cosmetic act definition). • On assessment PI found that the SAE was not related to Study drug so any action was not taken on the study drug.
  • 17. Conti…  According to the standard grading system the SAE was graded as  GRADE 3 – Severe (Require Hospitalization)  Appendix XI form  As per the guidelines the Appendix XI form was filled for reporting of SAE
  • 18. SAE Reporting – Appendix XI  Appendix XI details Details in Appendix XI were filled as follows 1. Patient Details • Initials and other relevent identifier – KMS, IP 524002 • Gender – Male • Age and DOB – 52 years, DOB-08/JAN/1962 • Weight - 58kgs • Height – 170cm
  • 19. Conti… 2. Suspected Drug : SAE not related to the IP • Generic name of the drug – blinded ADT 124 • Indication for which suspect drug was prescribed – dyslipidemia • Dosage form and strength – Auto-Injector 140 mg/ml • Daily dose and regimen – Blinded information • Route of Administration – IV • Starting Date and Time of day – NA (Subject was still undergoing screening)
  • 20. Other Treatments.. 3. Other Treatments – provide same information for concomitant drugs Generic name Indication s for drug was prescribd Dosage Form and strength Daily dose and regimen Route of administr ation Starting date and time of day Stopping Date and time Isosorbide Mononitrat e Chest Pain 30mg OD Oral 9/APR/14 Cont. Metformin Diabetes Mellitus 500mg OD Oral 9/APR/14 Cont. Asprin Myocardia l Infraction 75mg OD Oral 9/APR/14 Cont. Ramipril Hypertensi on 1.25mg OD Oral 9/APR/14 Cont. Metaprolol Hypertensi on 25mg OD Oral 9/APR/14 Cont.
  • 21. Appendix XI  4. Details of Suspected Adverse event were written in detailed manner (as per patient details in previous slides), full description of reaction including body site and severity, as well as the criterion for regarding the report as serious . In addition to a description of the reported signs and symptoms, diagnoses for the reaction were written in a detailed form. Medications prescribed and details of hospitalization were mentioned.
  • 22. Conti…  Start date of onset of reaction – 9/Apr/14  Stop date or duration of reaction – 12/Apr/14  Setting – Hospital 5. Outcome – Resolved 6. Details of the Investigator, name, Phn no, profession, address were mentioned. Date of reporting – 18/Apr/14 Date of reporting to EC – 18/Apr/14 and investigator signed the form
  • 23. Safety Reporting  After the phone call from the subject PI assessed the event as SAE and reported it to the members of sponsors/CRO by mail.  PI prepared a Submission letter for SAE , filled the details of appendix XI form, CIOMS form, filled and updated the event in e-CRF and in CRF  Submission letter and covering letter was submitted to EC and DCGI for reporting the SAE on 10th April 2014 i.e. next day of the event( as per guidelines and regulatory requirements)
  • 24. Conti…  EC and DCGI reviewed the SAE report and acknowledged it and sent a Receipt .  After the discharge of subject from the hospital PI prepared a follow up report and submitted it to EC and DCGI.  Outcome - SAE was resolved as the subject recovered from Accelerated Hypertension
  • 25. Conti…  All the forms, acknowledgments, lab reports, Letters and other documents were filed in patient file for further monitoring and audits.  Subject was randomized and he continued his participation in the study